Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of ...

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.SALT LAKE CITY ...

Recursion plucks J&J chief data science officer. Canaan adds ex-Pfizer R&D leader as venture partner. Obesity-focused Metsera unveils leadership team.

Recursion Pharmaceuticals has announced a research agreement with Sanofi Genzyme, to deploy its drug repurposing platform to identify new uses for Sanofi’s clinical stage molecules across dozens of ...

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...

Still, Recursion's use of AI is promising and could lead to lucrative breakthroughs. This is definitely a stock for aggressive, risk-tolerant investors.